Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Autor: Carl Chiang, Jacquelynn Copeland, Vanessa Raymont, Peter Connelly, Reto Kressig, Guy G. Potter, Daniel K. Burns, Stephen Pearson, Manish Saxena, Ann M. Saunders, Debra Fleischman, DeRen Huang, Thomas Leyhe, Gabriel Leger, Gigi Lefebvre, Mardik Donikyan, Natalie Denburg, Alex Knopman, Nancy Voight, James Burke, Philip Moore, James R. Burke, Margaret Newson, Stephen Haneline, Adam J. Schwarz, George Demakis, Joseph Butchart, Robert Mitchell, Mark Leibowitz, Michael Woodward, Robert Alexander, Concetta Forchetti, Emiliangelo Ratti, Andreas U. Monsch, Lon S. Schneider, Aaron Ritter, Joscelyn Agron-Figueroa, Fraser Inglis, Craig Curtis, Judith Neugroschl, Geraint Price, Mark Brody, Clark Johnson, Clive Ballard, Stephen Thein, Meredith Culp, Kristine Yaffe, Ahad Sabet, Walter Braude, Gregory Kirk, David Krefetz, Rupert Noad, Omid Omidvar, John Sass, Brenda L. Plassman, James Bergthold, Arne Klostermann, Haydn Till, Aaron Ellenbogen, Patrick Harrigan, Heinz-Peter Herbst, Joseph Kass, Lorna Wallace, Jennifer Robinson, Elliot Henderson, Felicia Goldstein, Christopher McWilliam, R. Clarnette, Jerry Halsten, Dan Rujescu, Silvana Micallef, Nestor Galvez-Jimenez, Jeffrey Ross, Dag Aarsland, Hugh Miller, Theresa Campbell, Jingtao Wu, Allan Levey, Liebhild Stratmann, Rosalyn Lai, Agnes Flöel, Richard Shingleton, Steve Higham, Pierre N. Tariot, Esteban Olivera, Sandra Carusa, Amanda Olley, Ricky Mofsen, Kathryn Goozee, Kara Lyons, Richard J. Brown, Marwan N. Sabbagh, Virginia De Sanctis, Jerome Goldstein, Hamid R. Sohrabi, Lefkos T. Middleton, Eugen Schlegel, Donna Munic-Miller, Sylvia Robinson, David Watson, Oda Ackermann, Ralph Votolato, Peter Bailey, Paul Massman, Daniel Gruener, Robert Perneczky, Frederick Schaerf, Craig W. Ritchie, Scott Losk, Christina Zimmerman, Mario Parra, Jill Crusey, Edward Zamrini, Christine Belden, Thomas Arnold, Alexander White, Linda Rice, Elizabeth Coulthard, Jane Martin, Anne Koplin, Rebecca Evans, Janet O'Neil, Oliver Peters, Raj Shah, Marshall Nash, Ronald Bradley, Kathleen A. Welsh-Bohmer, Howard Hassman, Scott Barton, Robert Cohen, Robert Stephenson, Jacobo Mintzer, Michael W. Lutz, Wendy Bond, Rachelle S. Doody, Ronald Hofner, Laura Samson

Publikováno v: The Lancet Neurology. 20:537-547

Background: The identification of people at risk of cognitive impairment is essential for improving recruitment in secondary prevention trials of Alzheimer's disease. We aimed to test and qualify a biomarker risk assignment algorithm (BRAA) to identi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::257db405d4f97f3e8da4448459b3c956
https://doi.org/10.1016/s1474-4422(21)00043-0